BRCA1 and cancer: Across cancer types, BRCA1/2 biallelic alterations were major contributors to HRD, especially in ovarian (45.9%/16.5%), breast (20.2%/11.9%), pancreatic (10.9%/12.7%), and prostate (5.9%/23.5%) cancers (Fig. 2F).